Fresenius to take majority stake in transfusion group:
This article was originally published in Clinica
Fresenius is to take a 51% stake in NPBI International, a manufacturer of transfusion systems for blood banks and equipment to produce blood components. NPBI, a Dutch company, has offices in Germany, Italy and the UK and production plants in the Netherlands and Brazil. It had turnover in 1996 of Fl146 million ($70 million).
You may also be interested in...
Oncology Center of Excellence is reviewing a research report on fluorouracil, and will next look to update cisplatin's label, but eventually must convince the reference product sponsor to submit the changes.
US FDA’s ‘Project Renewal’ requires lots of work and flexibility, Oncology Center of Excellence acknowledges. Side-benefit may be getting outside physicians to appreciate the value of drug labeling.
The pharmaceutical industry would lose bid to eliminate PUPSIT but win relaxed WFI in proposed EU GMP Annex I revision.